MAPS Public Benefit Corporation   Report issue

Foundation Phase 3
Founded: Santa Cruz CA United States (1986)

Organization Overview

First Clinical Trial
2013
NCT01793610
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Alternative names

MAPS Public Benefit Corp. | MAPS Public Benefit Corporation

Active Ingredients

Drugs in Phase 3 Trials (1)

3,4-Methyl​enedioxy​methamphetamine (13 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anorexia (Phase 2)

Anorexia Nervosa (Phase 2)

Binge-Eating Disorder (Phase 2)

Bulimia (Phase 2)

Feeding and Eating Disorders (Phase 2)

Stress Disorders, Post-Traumatic (Phase 3)

Stress Disorders, Traumatic (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 13
  • # of Trial APIs: 1